Therapeutics News and Research

RSS

Pharmaceutical and academic leaders come together to discuss biomarkers in ALS

Leaders from academic institutions, non-profit organizations, and pharmaceutical companies will meet in Cambridge, Mass., on Monday, May 19, to discuss biomarkers in amyotrophic lateral sclerosis (ALS).

19 May 2014

KineMed extends collaboration with CHDI Foundation to track pathogenesis of Huntington's disease

KineMed, Inc. and CHDI Foundation, Inc. announced today an extension of their collaboration that uses KineMed's translational biomarker platform to characterize and track the pathogenesis of Huntington's disease (HD) and evaluate potentially therapeutic interventions.

19 May 2014

Kamada announces top-line results from Phase II/III trial for treatment of inherited emphysema

Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, announces preliminary top-line results from the Phase II/III pivotal clinical trial in Europe and Canada of the Company's proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD or inherited emphysema).

16 May 2014

TCM announces winners of 26th Annual Industry Awards

The Tech Council of Maryland (TCM), Maryland's largest technology trade association for life science and technology, today announced the winners of its 26th Annual Industry Awards.

16 May 2014

Kymab raises US$40 million in Series B financing

Kymab, a monoclonal antibody biopharmaceutical company, announced today it has successfully raised US$40 million in a Series B financing.

16 May 2014

New dual-pronged approach for treating Niemann-Pick type C disease

By studying nerve and liver cells grown from patient-derived induced pluripotent stem cells (iPSCs), Whitehead Institute researchers have identified a potential dual-pronged approach to treating Niemann-Pick type C (NPC) disease, a rare but devastating genetic disorder.

16 May 2014

CVD risk factors may differ between men and women with type 2 diabetes, shows study

Type 2 diabetes greatly increases a person's risk of developing cardiovascular disease (CVD). A new study showing that cardiovascular risk factors such as elevated blood pressure and cholesterol levels differ significantly between men and women is published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

16 May 2014

UH pharmacy students earn awards for excellence in leadership, professional service and clinical skills from TSHP

University of Houston (UH) pharmacy students wrapped up the spring semester with a round of awards for excellence in leadership, professional service and clinical skills.

16 May 2014

Researchers test genomic sequencing for women with triple negative breast cancer

Indiana University cancer researchers are testing whether therapy incorporating advanced genomic technology will provide better outcomes than current treatments for those with an aggressive form of breast cancer.

15 May 2014

Transition Therapeutics begins TT-401 Phase 2 clinical study for treatment of type 2 diabetes

Transition Therapeutics Inc. today announced the dosing of the first patient in a Phase 2 clinical study of TT-401 (LY2944876), a drug candidate for the treatment of type 2 diabetes.

15 May 2014

Study: Lorazepam drug not effective in treating pediatric status epilepticus

A National Institutes of Health-sponsored study published in the Journal of the American Medical Association showed that lorazepam - a widely used but not yet Food and Drug Administration approved drug for children - is no more effective than an approved benzodiazepine, diazepam, for treating pediatric status epilepticus.

15 May 2014

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that principal investigator, Srdan Verstovsek, MD, PhD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 2, 2014 at the American Society for Clinical Oncology 2014 Annual Meeting.

15 May 2014

Eleven Biotherapeutics reports financial results and operational highlights for Q1 2014

Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results and operational highlights for the quarter ended March 31, 2014.

15 May 2014

EntreMed reports net loss of $1.5M in first quarter 2014

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, today reported financial results for the three months ended March 31, 2014.

15 May 2014

Isis Pharmaceuticals receives $3 million milestone payment from GSK

Isis Pharmaceuticals, Inc. announced today that it has earned a $3.0 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of a natural history study, which will support the advancement of one of the alliance programs.

15 May 2014

Sorrento Therapeutics prices underwritten public offering of 4,765,000 shares of common stock

Sorrento Therapeutics, Inc. ("Sorrento" or the "Company"), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced the pricing of an underwritten public offering of 4,765,000 shares of common stock at a public offering price of $5.25 per share.

15 May 2014

Kamada to present Phase 2/3 clinical trial results of AAT to treat alpha-1 antitrypsin deficiency

Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, will announce results from its Phase 2/3 clinical trial of its proprietary inhaled alpha-1 antitrypsin (AAT) to treat alpha-1 antitrypsin deficiency (AATD) in Europe and Canada on Friday, May 16, 2014, at approximately 7:30 a.m. Eastern time.

15 May 2014

Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Isis Pharmaceuticals, Inc. announced today positive data from a Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy.

14 May 2014

Researchers develop chip-like device to sort, store and retrieve individual living cells for study

A U.S. and Korean research team has developed a chip-like device that could be scaled up to sort and store hundreds of thousands of individual living cells in a matter of minutes. The system is similar to a random access memory chip, but it moves cells rather than electrons.

14 May 2014

MedImmune to present Phase IIb asthma data on benralizumab and tralokinumab at ATS conference

AstraZeneca today announced that MedImmune, its global biologics research and development arm, will present Phase IIb data on two novel investigational molecules – benralizumab and tralokinumab – at the upcoming American Thoracic Society 2014 International Conference being held in San Diego, California, 16-21 May.

14 May 2014

Therapeutics News and Research

Pharmaceutical and academic leaders come together to discuss biomarkers in ALS

KineMed extends collaboration with CHDI Foundation to track pathogenesis of Huntington's disease

Kamada announces top-line results from Phase II/III trial for treatment of inherited emphysema

TCM announces winners of 26th Annual Industry Awards

Kymab raises US$40 million in Series B financing

New dual-pronged approach for treating Niemann-Pick type C disease

CVD risk factors may differ between men and women with type 2 diabetes, shows study

UH pharmacy students earn awards for excellence in leadership, professional service and clinical skills from TSHP

Researchers test genomic sequencing for women with triple negative breast cancer

Transition Therapeutics begins TT-401 Phase 2 clinical study for treatment of type 2 diabetes

Study: Lorazepam drug not effective in treating pediatric status epilepticus

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Eleven Biotherapeutics reports financial results and operational highlights for Q1 2014

EntreMed reports net loss of $1.5M in first quarter 2014

Isis Pharmaceuticals receives $3 million milestone payment from GSK

Sorrento Therapeutics prices underwritten public offering of 4,765,000 shares of common stock

Kamada to present Phase 2/3 clinical trial results of AAT to treat alpha-1 antitrypsin deficiency

Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Researchers develop chip-like device to sort, store and retrieve individual living cells for study

MedImmune to present Phase IIb asthma data on benralizumab and tralokinumab at ATS conference

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News